Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers - PubMed (original) (raw)
Comparative Study
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
G Ferrari et al. Proc Natl Acad Sci U S A. 1997.
Abstract
A fundamental goal of current strategies to develop an efficacious vaccine for AIDS is the elicitation of broadly reactive cytotoxic T lymphocyte (CTL) reactivities capable of destroying virally infected targets. Recent application of recombinant canarypox ALVAC/HIV-1 vectors as vaccine immunogens in HIV-1,-noninfected volunteers has produced CTL responses in a significant number of vaccinees. Using a newly developed targeting strategy, we examined the capacity of vaccine-induced CTL to lyse autologous targets infected with a diverse group of viral isolates. CTL derived from recipients of a canarypox ALVAC/HIV-1 gp160 (MN) vaccine were found capable of lysing autologous CD4+ lymphoblasts infected with the prototypic LAI strain of HIV-1. When tested against autologous targets infected with primary HIV-1 isolates representing genetically diverse viral clades, CTL from ALVAC/gp160 recipients showed both a broad pattern of cytolysis in which viruses from all clades tested were recognized as well as a highly restricted pattern in which no primary isolates, including clade B, were lysed. Differences in the HLA haplotypes of the volunteers immunized with the envelope vector might be a major determinant of the relative breadth of their CTL response. In contrast to ALVAC/gp160 vaccinees, recipients of the ALVAC/HIV-1 immunogen containing envelope as well as gag and protease genes consistently had CTL reactivities effective against a spectrum of primary isolate-infected targets. These studies demonstrate for the first time that clade B-based canarypox vaccines can elicit broad CTL reactivities capable of recognizing viruses belonging to genetically diverse HIV-1 clades. The results also reinforce the impact of viral core elements in the vaccine as well as the pattern of major histocompatibility complex class I allelic expression by the vaccine recipient in determining the relative breadth of the cellular response.
Figures
Figure 1
The percentage of HIV-1-specific lysis against vaccinia/Env- and vaccinia/Gag-infected, autologous BLCL is reported subtracting the background lysis of control vaccinia-infected targets. Results for volunteers FII, FJ2, FIL, and IRQ are reported at E/T = 40:1 and for volunteers G0B, G0C, G0H, and IG9 at E/T = 50:1. (Upper) The CTL activities are directed against env determinants only. (Lower) The CTL are directed against both env and gag determinants.
Figure 2
The percentage of HIV-1-specific lysis against vaccinia/Env-infected or vaccinia/Gag-infected, autologous BLCL targets or HIV-1LAI-infected, autologous CD4+ lymphoblasts is reported subtracting the background lysis of control vaccinia-infected, autologous BLCL targets or uninfected, autologous CD4+ lymphoblast targets, respectively. Results for volunteers FII and FJ2 are reported at E/T = 40:1 and for volunteers G0B and G0H at E/T = 50:1.
Figure 3
The percentage of HIV-1-specific lysis against autologous CD4+ lymphoblasts infected with primary HIV-1 isolates representing the designated clades is reported subtracting the background lysis against uninfected, autologous CD4+ lymphoblast targets. Results for volunteers FII and FJ2 are reported at E/T = 40:1 and for volunteers G0B and IG9 at E/T = 50:1
Similar articles
- Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
Wilson SE, Pedersen SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, Tartaglia J, Celum CL, Sheppard HW. Wilson SE, et al. AIDS Res Hum Retroviruses. 1998 Jul 20;14(11):925-37. doi: 10.1089/aid.1998.14.925. AIDS Res Hum Retroviruses. 1998. PMID: 9686639 - A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Perales MA, Schwartz DH, Fabry JA, Lieberman J. Perales MA, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):27-35. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7648281 Clinical Trial. - Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
Ferrari G, Kostyu DD, Cox J, Dawson DV, Flores J, Weinhold KJ, Osmanov S. Ferrari G, et al. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1433-43. doi: 10.1089/08892220050140982. AIDS Res Hum Retroviruses. 2000. PMID: 11018863 Review. - Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
Siliciano RF, Bollinger RC, Callahan KM, Hammond SA, Liu AY, Miskovsky EP, Rowell JF, Stanhope PE. Siliciano RF, et al. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1349-52. doi: 10.1089/aid.1992.8.1349. AIDS Res Hum Retroviruses. 1992. PMID: 1361352 Review.
Cited by
- Current situation in the development of a preventive HIV vaccine.
Alcamí J, Joseph Munné J, Muñoz-Fernández MÁ, Esteban M. Alcamí J, et al. Enferm Infecc Microbiol Clin. 2005 Jul;23:15-24. doi: 10.1016/S0213-005X(05)75157-0. Epub 2009 Jan 6. Enferm Infecc Microbiol Clin. 2005. PMID: 38620211 Free PMC article. - The evolution of poxvirus vaccines.
Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M. Sánchez-Sampedro L, et al. Viruses. 2015 Apr 7;7(4):1726-803. doi: 10.3390/v7041726. Viruses. 2015. PMID: 25853483 Free PMC article. Review. - Human immunodeficiency virus vaccines.
Goepfert P, Bansal A. Goepfert P, et al. Infect Dis Clin North Am. 2014 Dec;28(4):615-31. doi: 10.1016/j.idc.2014.08.004. Epub 2014 Oct 5. Infect Dis Clin North Am. 2014. PMID: 25287587 Free PMC article. Review. - Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.
Kaleebu P, Njai HF, Wang L, Jones N, Ssewanyana I, Richardson P, Kintu K, Emel L, Musoke P, Fowler MG, Ou SS, Jackson JB, Guay L, Andrew P, Baglyos L, Cao H; HPTN 027 protocol team. Kaleebu P, et al. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):268-77. doi: 10.1097/01.qai.0000435600.65845.31. J Acquir Immune Defic Syndr. 2014. PMID: 24091694 Free PMC article. Clinical Trial. - Advances in antiviral vaccine development.
Graham BS. Graham BS. Immunol Rev. 2013 Sep;255(1):230-42. doi: 10.1111/imr.12098. Immunol Rev. 2013. PMID: 23947359 Free PMC article. Review.
References
- Mascola J R, Snyder S W, Weislow O S, Belay S M, Belshe R B, Schwartz D H, Clements M, Dolin R, Graham B S, Gorse G J, Keefer M C, McElrath M J, Walker M C, Wagner K F, McNeil J G, McCutchan F E, Burke D S. J Infect Dis. 1996;173:340–348. - PubMed
- Van Cott T C, Bethke F R, Burke D S, Redfield R R, Birx D L. J Immunol. 1995;155:4100–4110. - PubMed
- McMichael A, Walker B. AIDS. 1994;8:S155–S173. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials